[1] WANG Y,KURICHI J E,BLUMENTHAL N P,et al.Multiple variables affecting blood usage in lung transplantation[J]. J Heart Lung Transplant, 2006, 25(5): 533-538.
[2] CLAUSEN E,CANTU E.Primary graft dysfunction: what we know[J].J Thorac Dis, 2021, 13(11): 6618-6627.
[3] COSTA J,BENVENUTO L J,SONETT J R.Long-term outcomes and management of lung transplant recipients[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(2): 285-297.
[4] DIAMOND J M,LEE J C, KAWUT S M,et al.Clinical risk factors for primary graft dysfunction after lung transplantation[J]. Am J Respir Crit Care Med, 2013, 187(5): 527-534.
[5] HAYES D J,TUMIN D,YATES A R, et al.Transfusion with packed red blood cells while awaiting lung transplantation is associated with reduced survival after lung transplantation[J]. Clin Transplant, 2016, 30(12): 1545-1551.
[6] IDER M,NASERI A,OK M, et al.Serum sRAGE and sE-selectin levels are useful biomarkers of lung injury and prediction of mortality in calves with perinatal asphyxia[J]. Theriogenology, 2022, 181: 113-118.
[7] CHRISTIE J D,SHAH C V,KAWUT S M,et al.Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction[J]. Am J Respir Crit Care Med, 2009, 180(10): 1010-1015.
[8] MANGALMURTI N S,FRIEDMAN J L,WANG L C,et al.The receptor for advanced glycation end products mediates lung endothelial activation by RBCs[J]. Am J Physiol Lung Cell Mol Physiol, 2013, 304(4): L250-L263.
[9] RAO U,SHARMA M,MOHANAKUMAR T,et al.Prevalence of antibodies to lung self-antigens (Kα1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: Single center experience[J]. Transpl Immunol, 2019, 54: 65-72.
[10] SNYDER L D,WANG Z, CHEN D F, et al.Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients[J]. Chest, 2013, 144(1): 226-233.
[11] SPIESS B D,ROYSTON D,LEVY J H,et al.Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes[J]. Transfusion, 2004, 44(8): 1143-1148.
[12] DE BOER M T,CHRISTENSEN M C,ASMUSSEN M, et al.The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation[J]. Anesth Analg, 2008, 106(1): 32-44.
[13] ZALUNARDO M P,THALMANN C,SEIFERT B,et al.Impact of preoperative right-ventricular function and platelet transfusion on outcome after lung transplantation[J]. Eur J Cardiothorac Surg, 2011, 39(4): 538-542.
[14] ONG L P,THOMPSON E,SACHDEVA A,et al.Allogeneic blood transfusion in bilateral lung transplantation: impact on early function and mortality[J]. Eur J Cardiothorac Surg, 2016, 49(2): 668-674, 674.
[15] STERNBERG D I,SHIMBO D,KAWUT S M,et al.Platelet activation in the postoperative period after lung transplantation[J]. J Thorac Cardiovasc Surg, 2008, 135(3): 679-684.
[16] BORDERS C F,SUZUKI Y,LASKY J, et al.Massive donor transfusion potentially increases recipient mortality after lung transplantation[J]. J Thorac Cardiovasc Surg, 2017, 153(5): 1197-1203.
[17] WEBER D,COTTINI S R,LOCHER P,et al.Association of intraoperative transfusion of blood products with mortality in lung transplant recipients[J].Perioper Med (Lond), 2013, 2(1): 20.
[18] MASON D P,LITTLE S G,NOWICKI E R, et al.Temporal pattern of transfusion and its relation to rejection after lung transplantation[J]. J Heart Lung Transplant, 2009, 28(6): 558-563.
[19] YOUSSEF L A,SPITALNIK S L.Transfusion-related immunomodulation: a reappraisal[J]. Curr Opin Hematol, 2017, 24(6): 551-557.
[20] OECHSLIN P,ZALUNARDO M P,INCI I, et al.Established and potential predictors of blood loss during lung transplant surgery[J]. J Thorac Dis, 2018, 10(6): 3845-3848.
[21] BELLE-VAN M G, de JONG P A, de VALK H W, et al. Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients[J]. PLoS One, 2015, 10(12): e145597.
[22] VIVACQUA A, KOCH C G, YOUSUF A M, et al.Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both?[J]. Ann Thorac Surg, 2011, 91(6): 1780-1790.
[23] GELI J, CAPOCCIA M, MAYBAUER D M, et al.Argatroban Anticoagulation for Adult Extracorporeal Membrane Oxygenation: A Systematic Review[J]. J Intensive Care Med, 2022, 37(4): 459-471.
[24] MAGOULIOTIS D E, TASIOPOULOU V S, SVOKOS A A, et al.Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-analysis[J]. Gen Thorac Cardiovasc Surg, 2018, 66(1): 38-47.
[25] HOECHTER D J, SHEN Y M, KAMMERER T, et al.Extracorporeal Circulation During Lung Transplantation Procedures: A Meta-Analysis[J]. ASAIO J, 2017, 63(5): 551-561.
[26] KOSTER A, FARAONI D, LEVY J H.Antifibrinolytic Therapy for Cardiac Surgery: An Update[J]. Anesthesiology, 2015, 123(1): 214-221.
[27] BALSARA K R, MOROZOWICH S T, LIN S S, et al.Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation[J]. Interact Cardiovasc Thorac Surg, 2009, 8(1): 45-48.
[28] HERRINGTON C S, PREKKER M E, ARRINGTON A K, et al.A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation[J]. Clin Transplant, 2011, 25(1): 90-96.
[29] ENGOREN M,HABIB R H,HADAWAY J,et al.The effect on long-term survival of erythrocyte transfusion given for cardiac valve operations[J]. Ann Thorac Surg, 2009, 88(1): 95-100, 100-101.
[30] LEVI M, LEVY J H,ANDERSEN H F,et al.Safety of recombinant activated factor Ⅶ in randomized clinical trials[J]. N Engl J Med, 2010, 363(19): 1791-1800.
[31] BHASKAR B,ZEIGENFUSS M,CHOUDHARY J, et al.Use of recombinant activated Factor Ⅶ for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications[J]. Transfusion, 2013, 53(4): 798-804.
[32] FRANCHINI M,LIPPI G.Prothrombin complex concentrates: an update[J].Blood Transfus, 2010, 8(3): 149-154.
[33] SØRENSEN B, SPAHN D R,INNERHOFER P,et al. Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity[J].Crit Care, 2011, 15(1): 201.
[34] SCHICK K S,FERTMANN J M,JAUCH K W,et al.Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding[J]. Crit Care, 2009, 13(6): R191.
[35] SMITH I, PEARSE B L,FAULKE D J,et al.Targeted Bleeding Management Reduces the Requirements for Blood Component Therapy in Lung Transplant Recipients[J]. J Cardiothorac Vasc Anesth, 2017, 31(2): 426-433.
[36] KARKOUTI K,CALLUM J,WIJEYSUNDERA D N, et al.Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial[J]. Circulation, 2016, 134(16): 1152-1162.
[37] PARTOVI S,BRUCKNER B A,STAUB D,et al.Bloodless lung transplantation in Jehovah's Witnesses: impact on perioperative parameters and outcome compared with a matched control group[J]. Transplant Proc, 2013, 45(1): 335-341. |
